Treat-to-target in systemic lupus erythematosus: Where are we?

Roberto Ríos-Garcés, Gerard Espinosa, Ronald van Vollenhoven, Ricard Cervera*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Systemic lupus erythematosus (SLE) is the most paradigmatic disorder within systemic autoimmune diseases. The concept and principles of treat-to-target (T2T) in SLE were established half a decade ago and, since then, remarkable advances have been made. An international consensus was organized in order to define and unify the term remission, although plurality, with subtle nuances still exists and has not been overcome. Also, lupus low disease activity state (LLDAS) was coined as an alternative and, perhaps, more realistic target. Both of them have proven to be meaningful in terms of improving several outcomes, and have opened the path for future research in clinical trials. This review arises from the need to summarize the current state of some of the recommendations of the T2T task force.

Original languageEnglish
Number of pages6
JournalEuropean Journal of Internal Medicine
Volume74
DOIs
Publication statusE-pub ahead of print - 1 Jan 2020

Cite this